5592 Background: We sought to evaluate the short-term response rate, toxicity and potential molecular changes following treatment with metformin for simple (SEH) and complex endometrial hyperplasia without atypia (CEH). Methods: Women with newly diagnosedsimple or complex endometrial hyperplasia without atypia by endometrial biopsy or dilation & curettage were enrolled onto a prospective multi-institutional single arm clinical trial, and treated with metformin for 3 months (850 mg daily x 4 weeks, then twice daily for 8 weeks), followed by repeat biopsy. Pathologic response and toxicity (CTCAE 4.1) were assessed. Expression of the estrogen (ER) and progesterone (PR) receptor and the metformin transporters (OCT1, OCT3, PMAT, MATE1, MATE2) were evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded endometrial specimens pre- and post-treatment. Slides were scanned using the Aperio ScanScope, and digital images were analyzed using Aperio ImageScope software. We report proportions as %, along with their exact 95% confidence intervals. Pre- and post- comparisons were done using the Wilcoxon signed-rank test. Reported p-values were nominal, or unadjusted for multiple testing. Results: 18 patients enrolled, with 16 evaluable, of whom all completed treatment. 56% (9/16, 95% CI 30%, 80%) showed pathologic response (6/9 SEH, 2/5 CEH, 1/2 SEH/CEH). Common toxicities included diarrhea (67%), nausea (39%), flatulence (28%); all were grade 1 except for grade 2 diarrhea (n = 2), GERD (n = 1), and nausea (n = 1). Before metformin, the median % positive staining cells was 98.9% for ER, 89.9% for PR, 50.8% for MATE2, 98.4% for MATE1, 26.5% for PMAT, 87.5% for OCT1 and 68.6% for OCT3. Expression of MATE2 (50.8 to 60.4% positive cells; 86.1 to 120.6 H-score, p = 0.048) and OCT3 (68.6 to 91.7% positive cells; 116.8 to 136.5 H-score, p = 0.017, 0.057 respectively) increased after metformin treatment, whereas expression of MATE1, PMAT, OCT1, ER, PR did not change. Conclusions: Approximately half of the patients with endometrial hyperplasia without atypia responded to short-term metformin treatment. Preliminary exploratory comparisons seem to indicate that MATE2 and OCT3 expression (by % positive cells and H-score) increases with metformin treatment. Clinical trial information: NCT01685762.